# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JP Morgan assesses the specialty pharma sector, highlighting robust fundamentals and new product excitement. Key focus on Teva,...
JP Morgan analyst Chris Schott upgrades Amneal Pharmaceuticals (NASDAQ:AMRX) from Underweight to Neutral and announces $9 pr...
Barclays analyst Balaji Prasad maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target ...
Truist Securities analyst Les Sulewski maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy and raises the price target...
Raising Full Year 2024 GuidanceThe Company is raising its previously provided full year 2024 guidance. Updated GuidancePrior Gu...